(photo credit David Ahntholz)

About The Meeting

Advances in technology allow us to understand the human microbiota not as a static entity but as a complex, changing ecosystem that records substantial data about our lifestyles, our environmental exposures, and the people we live with. Here I discuss changes in the human microbiota associated with early life events such as delivery mode and antibiotics, the subsequent development of the microbiome throughout life, and even the development of the microbiome after death and its potential utility for forensics. Of particular value for toxicological studies is the ability to transfer the microbiome to germ-free mice, allowing individualized tests of function and subsequent therapies to be tested in personalized rodent models. Relating human to rodent microbiome timescales, especially for dietary studies, and relating multi-omics data in a timeseries context, remain outstanding challenges. Rapid progress is being made in these areas, and will allow far more powerful studies of the effects of drugs in mammalian hosts and our ability to stratify responders from non-responders for a wide range of therapies.

Our Spring 2017 meeting is generously sponsored by:

Silver Sponsors

Q2 Solutions

Sekisui Xenotech

Bronze Sponsors

National University

For more information on sponsoring our May meeting, please refer to our sponsorship guidelines.

Prior presentations:

Note: slides are displayed in a new window, left-click to advance, right-click to go back.

Speaker	PDF	Topic	Date
Kim L. R. Brouwer, Pharm.D., Ph.D.		Altered Disposition of Drugs and Bile Acids in Patients with Non-Alcoholic Steatohepatitis (NASH)	December 7, 2016
Les Benet, Ph.D.		The Use of BDDCS in Drug Development: The Observations, The Predictions, Understanding the Scientific Basis and The Extensions	April 19, 2016
Nicholas J. Schork, Ph.D.		Design and Implementation Issues in Clinical Trials Advancing Personalized Medicine	September 15, 2015
Robert P. Hanzlik, Ph.D.		Reactive Metabolites, Cellular Targets and Beyond	April 28, 2015
J. Ernest Simpson, Ph.D.		The Chemistry Of Wine	October 28, 2014
Lawrence J. Marnett, Ph.D., F.C.P		Next Generation NSAIDs That Selectively Inhibit Endocannabinoid Metabolism by COX-2	May 6, 2014
Lawrence J. Lesko, Ph.D., F.C.P.		Drug Interaction Studies: Differences and Similarities in How to Meet the Regulatory Expectations in FDA Guidance and EMA Guidelines	May 14, 2013
Thomas Tozer, Ph.D.		Pharmacokinetics of Protein Drugs	October 23, 2012
Shujuan Chen		Application of Animal Models for Human Glucuronidation	October 23, 2012
Caroline Decker		The Use of Modified Bacterial CYPs for Metabolite Generation	October 23, 2012
Mary Dwyer, Ph.D.		Cancer Therapeutics: A Novel Approach	October 23, 2012
Justin Hoffman PharmD MS		Population Pharmacokinetics (PK) of LopinavirDuring Pregnancy and Postpartum	October 23, 2012
David A. Yee		Observations on the Urine Metabolic Ratio of Oxymorphone to Oxycodone in Pain Patients	October 23, 2012
Nabil Hanna, Ph.D.		The Discovery and Development of Rituxan	April 10, 2012
Dr. Richard Kim		Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance	April 19, 2011
Dr. Jerry Galluppi		Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist	October 5, 2010
Dr. Dennis Smith		Does drug metabolism hold its future in its own hands?	April 27, 2010
Dr. Paul F. Hollenberg		Mechanism-Based Inactivation of Human Cytochromes P450	October 6, 2009
Dr. Jack H. Dean Dr. Thomas Baillie		Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective	May 19, 2009
Eric Johnson, Ph.D.		Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography	September 30, 2008
Dr. Kenneth E. Thummel, Ph.D.		Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics	May 7, 2008
Dr. Anthony Lu, Ph.D.		Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme?	September 12, 2007
Dr. Scott Obach, Ph.D.		Leveraging ADME Data In Metabolites In Safety Testing (MIST)	April 18, 2007
Dr. Sidney Nelson, Ph.D.		Drug Metabolism and Chemical Structural Alerts	September 27, 2006
Richard B. Kim, MD		Relevance and Utility of Transporters to Drug Discovery and Development	September 21, 2005
Dr. Frederick P. Guengerich, Ph.D.		Human Cytochrome P450 2A6 as a Case History:  Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450	April 27, 2005
Dr. Leslie Benet, Ph.D.		Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS	September 29, 2004
Dr. Christopher A. Lipinski, Ph.D.		ADME/Tox: How Low Can You Go And How Do You Recover?	April 21, 2004